259,798 Shares in Savara Inc (NASDAQ:SVRA) Acquired by Raymond James Financial Inc.

Raymond James Financial Inc. acquired a new stake in Savara Inc (NASDAQ:SVRA - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 259,798 shares of the company's stock, valued at approximately $798,000. Raymond James Financial Inc. owned about 0.15% of Savara as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. The Manufacturers Life Insurance Company grew its stake in shares of Savara by 9.0% during the third quarter. The Manufacturers Life Insurance Company now owns 44,956 shares of the company's stock worth $191,000 after purchasing an additional 3,706 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of Savara by 14.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company's stock worth $112,000 after buying an additional 4,732 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Savara by 5.1% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,815 shares of the company's stock valued at $533,000 after acquiring an additional 6,141 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of Savara by 14.0% in the 4th quarter. SG Americas Securities LLC now owns 51,589 shares of the company's stock valued at $158,000 after acquiring an additional 6,330 shares during the last quarter. Finally, Rhumbline Advisers raised its position in shares of Savara by 6.8% in the 4th quarter. Rhumbline Advisers now owns 141,425 shares of the company's stock valued at $434,000 after acquiring an additional 9,041 shares during the period. Institutional investors and hedge funds own 87.93% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Wells Fargo & Company initiated coverage on shares of Savara in a report on Friday, December 20th. They issued an "overweight" rating and a $8.00 target price on the stock. JMP Securities reiterated a "market outperform" rating and set a $9.00 target price on shares of Savara in a report on Thursday, December 19th. Finally, HC Wainwright restated a "buy" rating and issued a $6.00 price target on shares of Savara in a report on Friday, March 28th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $8.83.

Savara Stock Down 3.6 %

Shares of SVRA stock traded down $0.10 during trading on Thursday, reaching $2.64. The company's stock had a trading volume of 928,733 shares, compared to its average volume of 1,340,310. The company has a market cap of $455.75 million, a price-to-earnings ratio of -6.14 and a beta of 0.52. The business has a fifty day moving average price of $2.72 and a 200-day moving average price of $3.14. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. Savara Inc has a one year low of $2.26 and a one year high of $5.34.

Savara (NASDAQ:SVRA - Get Free Report) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The firm had revenue of $0.27 million for the quarter. Analysts anticipate that Savara Inc will post -0.45 earnings per share for the current year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.